Abstract
We evaluated the impact of antiretroviral-induced dyslipidemia on hepatitis C virus (HCV) biogenesis in human immunodeficiency virus (HIV)/HCV coinfected patients. This study used serum samples from antiretroviral-naive HIV/HCV patients initiating their first regimen as part of AIDS Clinical Trials Group study protocols (A5142, A5202). Initiation of antiretrovirals increased most lipoproteins and apolipoproteins. In the multivariable model, changes in apolipoproteins were associated with changes in log10 HCV RNA from baseline to week-24 of therapy. Off-target lipogenic changes need to be considered in the context of liver and other metabolic disease in HIV/HCV patients.
Original language | English (US) |
---|---|
Journal | Open Forum Infectious Diseases |
Volume | 2 |
Issue number | 2 |
DOIs | |
State | Published - Apr 1 2015 |
Keywords
- Apolipoprotein CIII
- Apolipoproteins
- HCV
- HCV RNA
- HIV
- Lipoproteins
ASJC Scopus subject areas
- Oncology
- Clinical Neurology